High-Dose-Rate Brachytherapy Plus External Beam Radiotherapy for T1 to T3 Prostate Cancer: An Experience in Taiwan

Urology

Volumn 70, Issue 1, 2007, Pages 101-105

  Chen, Yen Chao ^a   Chuang, Cheng Keng ^a   Hsieh, Ming Li ^a   Chen, Wen Cheng ^b   Fan, Kang Hsing ^a   Yeh, Chie Yi ^a   Lee, Chung Chi ^a   Hong, Ji Hong ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; SEMINAL VESICLE; SEXUAL FUNCTION; TAIWAN; TREATMENT OUTCOME; URETHRA STRICTURE; URINE RETENTION; UROGENITAL TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TAIWAN;

EID: 34447515216     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.008     Document Type: Article

References (30)

1. Republic of China Department of Health. Cancer Registry Annual Report (2002), Department of Health, Executive Yuan, Republic of China, Taipei, Taiwan
2. Pu Y.S. Prostate cancer in Taiwan: epidemiology and risk factors. Int J Androl 23 suppl 2 (2000) 34-36
3. Underwood W., De Monner S., Ubel P., et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 171 (2004) 1504-1507
4. Godley P.A., Schenck A.P., Amamoo M.A., et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 95 (2003) 1702-1710
5. Johnson T.K., Gilliland F.D., Hoffman R.M., et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol 22 (2004) 4193-4201
6. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
7. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
8. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 41 (1998) 525-533
9. Syed A.M., Puthawala A., Sharma A., et al. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 8 (2001) 511-521
10. Galalae R.M., Kovacs G., Schultze J., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 81-90
11. Deger S., Boehmer D., Turk I., et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol 41 (2002) 420-426
12. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 316-327
13. Hiratsuka J., Jo Y., Yoshida K., et al. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 684-690
14. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
15. Wang J.Z., Guerrero M., and Li X.A. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
16. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
17. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 55 (2000) 382-386
18. Roach III M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
19. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
20. Rubin P., Constine L.S., Fajardo L.F., et al., RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31 (1995) 1041-1042
21. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
22. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
23. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
24. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
25. Mullokandov E., and Gejerman G. Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. Int J Radiat Oncol Biol Phys (2004) 1063-1071
26. Hoskin P.J., Bownes P.J., Ostler P., et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 68 (2003) 285-288
27. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
28. Turner S.L., Adams K., Bull C.A., et al. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 54 (1999) 124-129
29. Incrocci L., Slob A.K., and Levendag P.C. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 52 (2002) 681-693
30. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911